|
Mesoblast Ltd.
(NASDAQ: MESO)
|
9:00 PM UTC, 01/15/26 | |||
|---|---|---|---|---|
| Last: $17.73 | Change: +0.09 | %Change: +0.51% | Volume: 181,974 | |
| Open: | $ 17.96 | Volume: | 181,974 | |
|---|---|---|---|---|
| High: | $ 18.02 | Yield(%) | 0.00 | |
| Low: | $ 17.69 | P/E Ratio (ttm): | n/a | |
| Dividend ($): | n/a | Market Cap ($): | 2.26B | |
| EPS ($) | -1.06 | Shares Out: | 128.29M |
| % Price Change (last 4 weeks): | -5.67 |
|---|---|
| % Price Change (last 13 weeks): | -1.73 |
| % Price Change (last 26 weeks): | 55.42 |
| % Price Change (last 52 weeks): | 3.16 |
| % Price Change (year to date): | -2.22 |
| Return on Equity (%): | -18.92 |
|---|---|
| Return on Assets (%): | -14.03 |
| Return on Invested Capital (%): | -15.10 |
| Gross Profit Margin (%): | 32.96 |
|---|---|
| Net Profit Margin (%): | -593.92 |
| Operating Profit Margin (%): | -363.58 |
|
|
|
| 50-day Moving Average: | $17.33 |
|---|---|
| 200-day Moving Average: | $14.57 |
| Avg. Daily Vol. (last 50 days): | 219,499 |
| Avg. Daily Vol. (last 200 days): | 231,351 |
| 52-wk high: | $21.50 |
| 52-wk low: | $9.61 |
| Bid: | $17.22 |
| Ask: | $17.48 |
|
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
|
|
Mesoblast Ltd.
55 Collins Street Level 38 Melbourne VI 3000 Phone: 61.3.9639.6036 Fax: 61.3.9639.6030 http://www.mesoblast.com |
| Earnings (1year) ($): | -0.85 |
|---|---|
| Annual Dividend ($): | 0.00 |
| Current P/E Ratio (ttm): | n/a |
| Book Value ($): | 4.67 |
| Cash Flow ($): | -0.75 |
| Price/Earnings (x): | n/a |
|---|---|
| Price/Sales (x): | 76.61 |
| Price/Book (x): | 2.33 |
| Price/Cash Flow (x): | n/a |
| Quick Ratio (x): | 1.77 |
|---|---|
| Current Ratio (x): | 1.99 |
| LT Debt/Equity (x): | 11.94 |
| Total Debt/Equity (x): | 21.45 |